Undisclosed DMD Program(s)
Duchenne Muscular Dystrophy
PreclinicalResearch & Discovery
Key Facts
Indication
Duchenne Muscular Dystrophy
Phase
Preclinical
Status
Research & Discovery
Company
About WaVe Life Sciences
Wave Life Sciences is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Its core strategy is built on the PRISM® platform, a toolkit for designing and developing stereopure oligonucleotides, including RNA editing and silencing therapies. The company is rapidly advancing a diversified pipeline, with key programs like WVE-006 for Alpha-1 antitrypsin deficiency and WVE-007 (INHBE siRNA) for obesity generating significant clinical interest. Wave is strategically positioning itself at the forefront of next-generation genetic medicines.
View full company profileTherapeutic Areas
Other Duchenne Muscular Dystrophy Drugs
| Drug | Company | Phase |
|---|---|---|
| Eteplirsen | CSL | Commercial |